Sanofi cuts its profit by 7% in the first quarter of 2021 to €1.56 billion

Sanofi cuts first-quarter 2021 profit by 7% to $1.9 billion (€1.56 billion). The French drugmaker posted net sales of $10.4 billion (€8.6 billion) between January and March, down 4.3% compared with the same period in 2020.

The French drugmaker posted a net profit of $1.9 billion (€1.56 billion) in the first quarter of 2021, down 7% from the first quarter of 2020, according to quarterly accounts released by the company. The group achieved net sales of $10.4 billion (€8.6 billion) between January and March, down 4.3% compared to the same period in 2020.

By business segment, the generics division fell by 9.8% to (€3.67 billion). The Specialty Medicines division, on the other hand, increased by 7.3% to $3.5 billion (€2.89 billion). Net sales in the Consumer Products business contracted by 14.4% to $1.37 billion (€1.13 billion), while the Vaccines segment grew by 0.7% to $1.1 billion (€915 million).

If you want to read more details about Sanofi and its financial results, download for free the Born2Invest mobile app. Our companion app keeps its readers up to date with the most recent market updates and the most important business news in the world.

Sanofi increased net sales of specialty drugs by 7.3% to $3.5 billion (€2.89 billion)

The cost of products sold was $3.25 billion (€2.68 billion) in the first quarter of 2021, down 6.3%. Selling and general expenses also fell by 6.3% to $2.65 billion (€2.19 billion), while research and development (R&D) accounted for an item of $1.53 billion (€1.26 billion), down 5.5%.

The United States accounted for 33.7% of Sanofi’s net sales, with $3.5 billion (€2.89 billion). Europe, with a decline of 5.6%, was in second place, with $2.7 billion (€2.23 billion). Finally, Sanofi’s net sales in the rest of the world rose 4.3% between January and March to $4.2 billion (€3.47 billion).

“Our strong first-quarter performance is the result of the continued execution of our strategy to achieve growth and bring innovative medicines to patients,” said Paul Hudson, CEO of Sanofi.

Sanofi expects to have Phase II trial results for its Covid-19 vaccine candidate “in the next month”

Hudson said that after initiating and completing enrollment of its Phase II trial for its recombinant Covid-19 vaccine candidate in the first quarter and “we expect results in the next month”.

Regarding partnerships for the production of Covid-19 vaccines, Sanofi announced that it will support BioNTech and Pfizer’s manufacturing and supply of the product by providing filling and finishing of more than 125 million doses at the Frankfurt (Germany) facility.

Moreover, Sanofi will also support the manufacture of Janssen’s Covid-19 vaccine through its vaccine manufacturing facility in Marcy l’Etoile (France). At this site, it will formulate and fill vials at a rate of twelve million doses per month.

__

(Featured image by Jernej Furman CC BY 2.0 via Flickr)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.